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Abstract  
Celiac disease (CeD) provides an opportunity 
to study the specificity underlying human T-
cell responses to an array of similar epitopes 
presented by the same human leukocyte 
antigen-II (HLA-II) molecule. Here, we 
investigated T-cell responses to the two 
immunodominant and highly homologous 
HLA-DQ2.5-restricted gluten epitopes, 
DQ2.5-glia-α1a (PFPQPELPY) and DQ2.5-
glia-ω1 (PFPQPEQPF). Using HLA-
DQ2.5:DQ2.5-glia-α1a and HLA-
DQ2.5:DQ2.5-glia-ω1 tetramers and single-
cell αβ T-cell receptor (TCR) sequencing, we 
observed that despite similarity in biased 
variable-gene usage in the TCR repertoire 
responding to these nearly identical 
peptide:HLA-II complexes, most of the T cells 
are specific for either of the two epitopes. To 
understand the molecular basis of this 
exquisite fine specificity, we undertook Ala 
substitution assays revealing that the p7 
residue (Leu/Gln) is critical for specific 
epitope recognition by both DQ2.5-glia-α1a 
and DQ2.5-glia-ω1 -reactive T-cell clones. We 
determined high-resolution   binary crystal 
structures of HLA-DQ2.5 bound to DQ2.5-
glia-α1a (2.0 Å) and DQ2.5-glia-ω1 (2.6 Å). 
These structures disclosed that differences 
around the p7 residue subtly alter the 
neighboring sub-structure and electrostatic 
properties of the HLA-DQ2.5-peptide 
complex, providing the fine specificity 
underlying the responses against these two 
highly homologous gluten epitopes. This study 
underscores the ability of TCRs to recognize 
subtle differences in the peptide:HLA-II 
landscape in a human disease setting. 
 
Introduction 
The αβ T-cell antigen receptor (TCR) recognizes 
peptide when presented by a given Major 
Histocompatibility Complex (MHC) molecule 
(1). In celiac disease (CeD), an autoimmune-like 
and HLA-associated disorder, disease-driving T 
cells recognize deamidated cereal gluten 
peptides when presented by HLA-DQ2.5, HLA-
DQ8 or HLA-DQ2.2 (2). Over 90 % of the CeD 
patients express HLA-DQ2.5, while the 
remainder express HLA-DQ8 or HLA-DQ2.2. 
The gluten proteome is extremely complex, 
comprising hundreds of proteins  (termed α-, γ-, 
and ω-gliadins and high- and low-molecular 
weight glutenins) (3). This system is remarkable 
in that there is natural immune exposure to a vast 
array of similar peptide sequences, and strikingly, 
the subjects who develop CeD make T-cell 
responses to a limited number of epitopes, many 
of which share substantial homology (4). In 
HLA-DQ2.5 associated CeD, most patients 
respond to DQ2.5-glia-α1a, DQ2.5-glia-α2, 
DQ2.5-glia-ω1 and DQ2.5-glia-ω2 epitopes (5), 
while most patients expressing HLA-DQ8 
respond to DQ8-glia-α1 (6). Hence, these 
epitopes are termed immunodominant epitopes.  
T cells reactive with immunodominant epitopes 
are persistent for decades in the patients (7). 
Such T cells, expressing gut homing markers, 
can be isolated from gut biopsies and from 
peripheral blood albeit at much lower frequency 
in blood (7). 
Studies of TCRs recognizing immunodominant 
HLA-DQ2.5 and HLA-DQ8 restricted gluten 
epitopes have demonstrated biased usage of 
variable (V)-gene segments (6,8-13). DQ2.5-
glia-α2-specific TCRs exhibit repeated gene 
usage of TRAV26-1/TRBV7-2 with a conserved 
CDR3β motif harboring a non-germline-encoded 
Arg residue (8,9,12). The TCRs specific for 
DQ2.5-glia-ω2 also display biased usage of 
TRAV4 and TRBV4 gene segments (12). DQ2.5-
glia-α1a-specific TCRs demonstrate biased 
expression of TRAV4 and TRBV20-1 or TRBV29-
1 genes (10). Similarly, the majority of DQ8-
glia-α1-specific T cells express TRBV9 
preferentially paired with TRBV26-2, expressing 
a non-germline encoded Arg residue in the 
CDR3β loop (6,11,13). The TRBV9-negative T 
cells specific to DQ8-glia-α1 also show biased 
usage of TRAV8-3/TRBV6-1+ TCRs, also with a 
conserved non-germline encoded Arg residue in 
the CDR3β loop (11). 
Recently, structural studies have provided 
molecular insight into TCR recognition of gluten 
epitopes when presented by HLA-DQ8 or HLA-
DQ2.5 (6,10,11,13). Three crystal structures of 
TRAV26-1/TRBV7-2-TCR:HLA-DQ2.5:DQ2.5-
glia-α2 complexes revealed that the TRBV7-2 
bias is mostly attributed to the interactions 
mediated by the CDR3β loop and that the 
conserved non-germline encoded Arg in this 
loop serves as a lynchpin in the peptide:HLA-II 
interaction (10). A crystal structure of 
TRAV4/TRBV20-1 TCR:HLA-DQ2.5:DQ2.5-
glia-α1a complex uncovered that the TRAV4 bias 
is a consequence of interactions between the 
germline-encoded TCR residues and HLA-
DQ2.5 (10). Crystal structures of TRAV26-
2/TRBV9-TCR:HLA-DQ8:DQ8-α1-gliadin and 
TRAV20/TRBV9-TCR:HLA-DQ8:DQ8-α1-
gliadin ternary complexes revealed that 
germline-encoded residues interacting with the 
HLA-DQ8 molecule and gliadin peptide residues 
formed the basis for the TRBV9 bias (6,11,13). 
These two crystal structures together with a 
crystal structures of a complex of TRAV8-
3/TRBV6-1-TCR:HLA-DQ8:DQ8-α1-gliadin (11) 
revealed that diverse TCR gene usage by DQ8-
restricted gluten-specific T cells converges into a 
consensus binding that is mediated by germline 
or non-germline encoded Arg residue. However, 
it remains unclear whether highly homologous 
gluten epitopes would generate cross-reactive or 
highly specific T cell responses.  
Here, we have studied the T-cell response 
towards the epitopes DQ2.5-glia-α1a 
(PFPQPELPY) and DQ2.5-glia-ω1 
(PFPQPEQPF). These immunodominant gluten 
epitopes in CeD are highly homologous, with 
only two amino acid differences in the 9-mer 
core region. Despite the epitope similarity, we 
found that the majority of patient-derived T cells, 
both isolated from blood or the celiac gut lesion, 
are specific for either of the two epitopes with 
limited cross-reactivity. This suggests that there 
are important differences in how T cells 
recognize these peptide:HLA-II complexes, as 
the immune system of the patients are exposed 
simultaneously to both epitopes when they 
consume gluten-containing food. To explore the 
basis for specific recognition of the homologous 
epitopes, we performed T-cell proliferation 
assays with amino-acid substituted epitopes, 
undertook single-cell TCRαβ-gene sequencing 
and solved the crystal structures of HLA-DQ2.5 
complexed with either DQ2.5-glia-α1a or 
DQ2.5-glia-ω1. Despite biased usage of common 
V genes, the majority of the T cells were specific 
to only one epitope. The p7 residue in both 
epitopes was critical for the specific TCR 
recognition by the discriminatory T-cell clones 
(TCCs). The crystal structures of the two 
peptide:HLA-DQ2.5 complexes, whilst similar, 
exhibited local structural perturbations around 
the p7 residue. Hence, this study demonstrates 
the ability of TCR to distinguish subtle 
differences in peptide:HLA-II topology. 
Consequently, in human T-cell mediated 
diseases like CeD, discrete alterations in the 
peptide:HLA-II landscape can profoundly shape 
the disease-driven immune response. 
Results 
Majority of T cells in blood and gut of CeD 
patients specific for DQ2.5-glia-α1a or DQ2.5-
glia-ω1 show exquisite fine specificity  
We identified distinct populations of CD4+ T 
cells that bound the HLA-DQ2.5:DQ2.5-glia-α1a 
or HLA-DQ2.5:DQ2.5-glia-ω1 tetramers in 
blood and gut of 12 CeD patients. (Fig. 1A). The 
relative ratio of CD4+ T cells positive to both 
DQ2.5:DQ2.5-glia-α1a- and DQ2.5:DQ2.5-glia-
ω1-tetramers with CD4+ T cells that are positive 
to either of the two tetramers in samples obtained 
from 11 CeD patients was 0.06 (mean). This 
suggests that  the majority (~ 95 %) of these 
CD4+ T cells   recognize either of the two 
tetramers  (Fig. 1B, Table S1) indicating that 
despite only two amino acids difference in the 9-
mer core region of the two gliadin peptides, most 
of the in vivo primed T cells in blood and gut of 
CeD patients discriminate between the two 
epitopes.  
 
The HLA-DQ:gluten tetramers (including HLA-
DQ2.5:DQ2.5-glia-α1a and HLA-DQ2.5:DQ2.5-
glia-ω1) give staining of effector memory CD4 T 
cells of CeD patients, but not of healthy subjects 
(14,15). We validated the specific staining of 
HLA-DQ2.5:DQ2.5-glia-α1a vs HLA-
DQ2.5:DQ2.5-glia-ω1 tetramers with TCCs that 
were generated from tetramer-sorted cells by 
antigen-free expansion and cloning by limited 
dilution. On re-testing of antigen specificity, all 
(nine) TCCs generated from PBMCs of the 
patient CD1383, stained with the tetramer used 
for sorting and showed a proliferative response 
towards the respective peptide (Fig. 1C and Fig. 
1D). One of the five TCCs generated from 
HLA-DQ2.5:DQ2.5-glia-α1a tetramer binding 
CD4+ T cells and one of four of the TCCs 
generated from HLA-DQ2.5:DQ2.5-glia-ω1 
tetramer binding CD4+ T cells stained with 
both the tetramers and gave a response to both 
peptides in T-cell proliferation assays. The 
cross-reactive T-cell clones displayed a higher 
fluorescence intensity to the tetramer originally 
used for their isolation. None of the nine TCCs 
stained with the other HLA-DQ2.5:gluten 
tetramers (HLA-DQ2.5:DQ2.5-glia-α2, HLA-
DQ2.5:DQ2.5-glia-ω2 and CLIP2), indicating 
the antigen specificity of the tetramer staining 
(Fig. 1C). In addition, none of these TCCs 
showed response to any other gluten epitopes 
when tested in a T-cell proliferation assay 
against a panel of known gluten peptides at a 
high concentration of 10 µM (Fig. 1D). Taken 
together, the results of the HLA-DQ:gluten 
tetramer staining of T cells in blood and gut as 
well as the proliferation assay and HLA-
DQ:gluten tetramer staining of established T-cell 
clones (the low number here prevents an exact 
estimate of cross-reactivity), strongly indicate 
that T cells of CeD patients generally 
discriminate between the two epitopes. 
 
The p7 residue of the DQ2.5-glia-α1a and 
DQ2.5-glia-ω1 epitopes is critical for T-cell 
recognition  
To explore the differences in recognition of these 
two highly homologous epitopes we measured 
the effect of single Ala substitutions at each 
position in the two epitopes (Table 1) in a T-cell 
proliferation assay. The sequences of the 
peptides used in these T-cell proliferation assays 
were identical to the epitope sequences that were 
part of the HLA-DQ:gluten tetramers. In this 
analysis TCCs that stained with the HLA-
DQ2.5:DQ2.5-glia-α1a or HLA-DQ2.5:DQ2.5-
glia-ω1 tetramers and that had reactivity with 
only one of the two epitopes, were tested (Table 
2). Reactivity pattern of the DQ2.5-glia-α1a-
specific- and DQ2.5-glia-ω1-specific TCCs to 
the single Ala-substituted DQ2.5-glia-α1a and 
DQ2.5-glia-ω1 peptides were normalized to the 
response to the wild-type peptide. 
 
Both DQ2.5-glia-α1a-(Fig. 2A) and DQ2.5-glia-
ω1-specific (Fig. 2B) TCCs lost reactivity on Ala 
substitution at p2 and p7. However, substitution 
at p9, a position that differs between the two 
epitopes, had no effect on the reactivity of the 
TCCs. This is in line with the observations from 
a previous study where p7 was critical, p9 was 
dispensable and the p2 had variable effects on T-
cell recognition of the DQ2.5-glia-α1a epitopes 
by the DQ2.5-glia-α1a-specific TCCs (10). 
Unique to all DQ2.5-glia-α1a-specific TCCs was 
the loss of reactivity on Ala substitution of 
residues p6 and p8. Two of the three TCCs lost 
reactivity on substitution at p3 and p4 while the 
third TCC was sensitive to substitution at p5. 
DQ2.5-glia-ω1-specific TCCs exhibited varying 
responses to Ala substitutions at positions other 
than p2 and p7. Substitution at p3 and p8 
resulted in loss of reactivity in three of four 
TCCs. In brief, the p2 and p7 amino acids were 
important for T-cell recognition of both the 
DQ2.5-glia-α1a and DQ2.5-glia-ω1 epitopes. 
 
To further investigate the basis of TCR 
specificity, T-cell proliferative assays were used 
to analyze the reactivity of DQ2.5-glia-α1a- and 
DQ2.5-glia-ω1-specific (Fig. 2C and Fig. 2D) 
TCCs against chimeric peptide with a single 
amino acid exchange at position p7 and p9 of 
DQ2.5-glia-α1a (α1_Qp7L, α1_Fp9Y) and 
DQ2.5-glia-ω1 (ω1_Lp7Q, ω1_Yp9F) (Table 3). 
Since the 9-mer core sequences of the DQ2.5-
glia-α1a and DQ2.5-glia-ω1 differ only at p7 and 
p9, the pair of chimeras α1_Qp7L and ω1_Yp9F, 
as well as the pair of α1_Fp9Y and ω1_Lp7Q, 
will have identical 9-mer core sequence but 
different flanking sequences. We observed that 
the responses of DQ2.5-glia-α1a- or DQ2.5-glia-
ω1-specific TCCs towards these two pairs of 
chimeras with identical 9-mer core sequence 
were similar, suggesting that flanking region is 
not contributing to the differential reactivity. We 
observed that both DQ2.5-glia-α1a-specific- (Fig. 
2C) and DQ2.5-glia-ω1-specific TCCs (Fig. 2D) 
recognized chimeric p9 peptides suggesting that 
this residue is dispensable. The majority of 
specific TCCs lost their reactivity when the p7 
residue was exchanged. However, these specific 
TCCs showed reactivity with chimeric peptides 
that had unchanged p7, i.e. DQ2.5-glia-α1a- and 
DQ2.5-glia-ω1-specific TCCs reacted with 
ω1_Lp7Q and α1_Qp7L, respectively. This 
observation highlights the importance of p7 in 
the specific T-cell recognition of DQ2.5-glia-α1a 
or DQ2.5-glia-ω1.  
 
High similarity in V-gene usage in TCRs 
specific for DQ2.5-glia-α1a and DQ2.5-glia-ω1  
To examine the CeD patient T-cell repertoire 
reactive to HLA-DQ2.5:DQ2.5-glia-α1a and 
HLA-DQ2.5:DQ2.5-glia-ω1, we isolated single 
CD4+ T cells directly from blood or gut biopsies 
of CeD patients using HLA-DQ2.5 tetramers and 
determined the sequences of rearranged TCRα 
and TCRβ gene pairs (Table 4). We looked at the 
overall usage of TRAV or TRBV gene segments. 
In cases of dual V-gene usage, each V gene was 
given a half score. For DQ2.5-glia-α1a, 165 
single T cells isolated from 11 CeD patients 
produced 116 unique clonotypes expressing 37 
TRAV and 26 TRBV genes (Fig. 3A and Fig. S1). 
Similar analysis of 113 DQ2.5-glia-ω1-specific 
T cells isolated from 11 CeD patients produced 
99 unique clonotypes expressing 35 TRAV and 
30 TRBV genes (Fig. 3A and Fig. S1). We then 
calculated pair-wise Morisita-Horn index to 
analyze the similarity in TRAV and TRBV usage, 
where higher index value indicates higher 
similarity. We found high similarity in both 
TRAV and TRBV usage (0.74 and 0.65, 
respectively) between DQ2.5-glia-α1a- and 
DQ2.5-glia-ω1-specific TCRs (Fig. 3A, Fig. 
S2A). The similarity between DQ2.5-glia-α1a- 
and DQ2.5-glia-ω1-specific TCRs was highest 
when compared with the previously published 
(12) V-gene usage in T cells specific for DQ2.5-
glia-α2 and DQ2.5-glia-ω2. (Fig. S2A). 
 
We examined the five most expressed TRAVs 
and TRBVs in TCRs specific for DQ2.5-glia-α1a- 
and DQ2.5-glia-ω1 and observed similar genes 
being preferentially expressed (Fig. 3B). Of note, 
TRBV29-1 and TRBV20-1, which were expressed 
as the most dominant TRBV in each of the two 
repertoires, are phylogenetically closely related 
(10). The TRAV35, TRAV4, TRAV12-2, TRBV29-
1 or TRBV20-1 and TRBV5-1 were the most 
frequently expressed TRAV- and TRBV-gene-
segments in both TCR repertoires. Further, for 
both DQ2.5-glia-α1a and DQ2.5-glia-ω1-specific 
TCRs we did not observe preferential pairing of 
TRAV and TRBV (Fig. S3).  
 
We also performed similar analysis of unique 
clonotypes obtained by paired TCRα and TCRβ 
sequencing of single CD4+ T cells isolated from 
in vitro cultured T-cell line (TCL) generated 
from gut biopsies of CeD patients using the 
HLA-DQ2.5:DQ2.5-glia-α1a (n = 50) or HLA-
DQ2.5:DQ2.5-glia-ω1 tetramers (n = 20) (Table 
4 and Fig. S1, Fig. S2B). The TRAV and TRBV 
usage for both epitopes in data derived from T 
cells that were directly isolated from blood or gut 
biopsies was generally reproduced in the data 
obtained from TCLs.  
 
We then aligned the CDR3α and CDR3β 
sequences of the TCRs specific for DQ2.5-glia-
α1a and DQ2.5-glia-ω1 (Fig. 3C) to analyze the 
CDR3 amino acid usage and positioning. The T 
cells were isolated using HLA-DQ2.5:DQ2.5-
glia-α1a or HLA-DQ2.5:DQ2.5-glia-ω1 
tetramers, either directly from blood or gut 
biopsies or from in vitro cultured TCLs from gut 
biopsy. We did not observe any significant 
selection pattern in the amino acid usage and 
positioning in the CDR3 sequences.  
 
We then examined the most frequently expressed 
V-genes in TCRs specific for the four 
immunodominant gluten epitopes (DQ2.5-glia-
α1a, DQ2.5-glia-ω1, DQ2.5-glia-α2 and DQ2.5-
glia-ω2). We analyzed unique clonotypes 
obtained by paired TCRαβ sequencing of single 
T cells isolated either from TCLs or directly 
from blood or gut biopsies of CeD patients using 
HLA-DQ2.5 tetramers (Fig. S2B).  TRAV4 was 
among three most frequently used V-gene 
segments in the TCR repertoires specific for all 
the four epitopes. As all these gluten epitopes are 
restricted by HLA-DQ2.5, this feature of TRAV4 
bias could be dependent on HLA interactions.  
 
Crystal structures of the DQ2.5-glia-α1a and 
DQ2.5-glia-ω1 complexes 
To gain an understanding of how two highly 
homologous epitopes give rise to two separate 
populations of T cells, we examined the 
corresponding peptide:HLA-II landscapes. Given 
the limited extent of cross-reactivity between the 
two gliadin determinants, it was unclear whether 
they would sit differently or within the same 
register in the HLA-DQ2.5 molecule. The 
observations made from the Ala substitution 
experiment performed on the TCCs is also based 
on the assumption that the substituted peptides 
bind in the identical binding registers. To 
establish this, we determined, to high resolution, 
the crystal structures of HLA-DQ2:DQ2.5-glia-
α1a (2.0 Å) and HLA-DQ2:DQ2.5-glia-ω1 (2.6 
Å) (Fig. 4A, 4B and Table 5) for data collection 
and refinement statistics). These complexes were 
solved with same linker peptide for both epitopes 
and accordingly any structural variation between 
these two binary complexes could be attributed 
to differences in the two epitopes bound within 
the antigen-binding cleft. While the crystal 
symmetry for the two crystals were different 
(P222 for DQ2.5-glia-α1 versus C121 for DQ2-
glia-ω1), the crystal packing of the two 
structures was overall similar and, notably, with 
no crystal contacts involving the peptide 
positions p7 and p9. The HLA-DQ2.5:DQ2.5-
glia-α1a structure aligned well with previously 
determined binary HLA-DQ2.5:DQ2.5-glia-α1a 
structure that was solved at lower resolution (16). 
The higher resolution structure (reported here) 
will be compared to the HLA-DQ2.5:DQ2.5-
glia-ω1 structure. The electron densities 
corresponding to the two peptides were clear 
(Fig. S4).  
 
Comparison of the HLA-DQ2.5:DQ2.5-glia-α1a 
and the HLA-DQ2.5:DQ2.5-glia-ω1 structures 
revealed minor differences (root mean square 
deviation (r.m.s.d.) = 0.32 Å for Cα atoms of the 
peptide binding domain), revealing that the two 
epitopes did not bind in a different register 
within the HLA-DQ2.5 molecule (Fig. 4C, 4D). 
The p7 residue was an anchor residue in both 
complexes (solvent accessible surface area of 
p7L and p7Q was 29.5Å2 and 20.7Å2, 
respectively, corresponding to 17% and 11% of 
the values for GXG).  The interactions between 
the DQ2.5-glia-α1a and DQ2.5-glia-ω1 peptides 
and HLA-DQ2.5 were essentially conserved (Fig. 
4A, 4B). Nevertheless, differences were apparent 
in the local environment of the peptide residues 
p7 and p9 (p7-Leu and p9-Tyr in HLA-
DQ2.5:DQ2.5-glia-α1a; p7-Gln and p9-Phe in 
HLA-DQ2.5:DQ2.5-glia-ω1). These differences 
coincided with an adjustment (up to 0.9 Å) in the 
positioning of the HLA-DQ2.5 β chain helix 
directly adjacent to p7 (Fig. 4C). The p7 
difference between the peptides altered how each 
peptide was H-bonded to HLA-DQ2.5. Namely, 
in HLA-DQ2.5:DQ2.5-glia-α1a, Lys71β formed 
a H-bond to the sidechain of p4-Gln, whereas in 
HLA-DQ2.5:DQ2.5-glia-ω1, it H-bonded to the 
backbone of p5-Pro, thus freeing p4-Gln to form 
an additional H-bond to Ser28β at the floor of 
the peptide binding cleft (Fig. 4A, 4B). These 
structural perturbations also led to electrostatic 
alterations around the P7 residue (Fig. 4E, 4F). 
These differences are clearly sufficient to be 
discerned by T cells being specific for either of 
the two homologous epitopes.  
 
 
To confirm that TCRs can discriminate between 
these two epitopes, we undertook surface 
plasmon resonance-based experiments using the 
HLA-DQ2.5-glia-α1a responsive TCRs (S2 and 
L6) (10) run over HLA-DQ2.5-glia-α1a and 
HLA-DQ2.5-glia-ω1 (Fig. 5). We found that the 
S2 TCR specifically recognized HLA-DQ2.5-
glia-α1a only and hence discriminated between 
HLA-DQ2.5-glia-α1 and HLA-DQ2.5-glia-ω1. 
The L6 TCR, however, bound HLA-DQ2.5-glia-
α1a HLA-DQ2.5-glia-ω1 with similar affinity. 
Taken together, the functional data and affinity 
measurements suggest that, whilst a small 
population of TCRs is able to cross-react with 
the two highly homologous gliadin epitopes, the 
majority of TCRs lack cross-reactivity. 
Discussion 
The CD4+ T-cell response to gluten epitopes 
presented by the disease-predisposing HLA-DQ 
molecules is an essential part of the pathogenesis 
of CeD. Here we have studied two homologous 
and immunodominant gluten epitopes, DQ2.5-
glia-α1a (PFPQPELPY) and DQ2.5-glia-ω1 
(PFPQPEQPF). Despite only two amino acids 
difference in the 9-mer core region of the 
epitopes, the majority (~ 95 %) of T cells in 
blood and gut of CeD patients discriminate 
between the two epitopes with only a proportion 
of the T cells being cross-reactive. We found that 
the p7 residue was uniformly critical in both 
epitopes for discriminatory TCR recognition by 
all TCCs. Accordingly, we addressed the 
molecular basis underpinning the fine specificity 
of this response. 
The p7 residues served as anchor residues in 
both HLA-DQ2.5:DQ2.5-glia-α1a and HLA-
DQ2.5:DQ2.5-glia-ω1 and their sidechains were 
only partially exposed in the binary crystal 
structures. Notwithstanding, it is striking that the 
p7 residue is critical for specific T-cell 
recognition of both DQ2.5-glia-α1a and DQ2.5-
glia-ω1 as well as  DQ2.5-glia-α2 and DQ2.5-
glia-ω2. In ternary crystal structures of three 
unique complexes of TCR:HLA-DQ2.5:DQ2.5-
glia-α2, the large sidechain of p7-Tyr forms 
critical interactions with the TCR, explaining its 
vital role for T-cell recognition of this epitope. 
However, the ternary structure of the S2 TCR 
(TRAV4*01-TRBV20-1*01) specific for the 
DQ2.5-glia-α1a epitope in complex with HLA-
DQ2.5 (10) revealed that this TCR does not 
make a direct contact with the less accessible p7-
Leu residue. In spite of this, the TCC from which 
the S2 TCR was derived, along with ten other 
DQ2.5-glia-α1a-specific TCCs, uniformly lost 
reactivity towards DQ2.5-glia-α1a on p7 
substitution in T-cell proliferation assays (10). 
The S2 TCR does discriminate between DQ2.5-
glia-α1a and DQ2.5-glia-ω1, suggesting that 
even though the p7-Leu is not making direct 
contact to the TCR it is, in some way, 
influencing antigen recognition. To address this 
conundrum, we determined the crystal structures 
of HLA-DQ2.5 complexed with the DQ2.5-glia-
α1a and DQ2.5-glia-ω1 epitopes, which revealed 
that the two epitopes were accommodated by 
HLA-DQ2.5 using the same register. While the 
two peptide-HLA-DQ2.5 binary complexes were 
similar, differences around the p7 residue altered 
the neighboring sub-structure of the HLA-DQ2.5 
molecule and associated electrostatic properties. 
Despite these relatively subtle differences in 
peptide:HLA-II topologies observed for the two 
immunodominant gluten epitopes, the S2 TCR 
must be able to detect them in a discriminatory 
manner. In the S2 TCR ternary complex, these 
p7 neighboring residues (specifically, HLA-
DQ2.5 Asp66β, Glu69β and Arg70β) form an 
extensive interface with CDR1α, CDR3β and α-
framework residues of the S2 TCR, suggesting 
that the nature of this local environment is 
involved in epitope discrimination. Similar to the 
previous study, we found that for DQ2.5-glia-
α1a-specific TCCs the p7-Leu was uniformly 
critical in specific TCR recognition. The DQ2.5-
glia-α1a-specific TCCs analyzed in the two 
studies use many different TRAV/TRBV pairings 
suggesting that this critical role of p7 is not 
contingent of a particular TCR gene usage. 
Interestingly, the p7-Gln of the DQ2.5-glia-ω1 
epitope was also critical in specific TCR 
recognition for the DQ2.5-glia-ω1-specific TCCs 
that also express fairly diverse TCRs. These 
observations suggest that the different p7 amino 
acids in DQ2.5-glia-α1a and DQ2.5-glia-ω1 
epitopes induce subtle differences that are sensed 
by the TCRs giving discriminatory recognition 
of the two peptide:HLA-II complexes. Similar 
features of impact on TCR recognition by a 
MHC buried anchor residues, were observed for 
I-Ek and a hemoglobin epitope where 
substitution at the p6 residue affected T-cell 
recognition (17). Hence, these results indicate 
that anchor residues that are buried in the MHC 
II and make no direct contact with the TCR, can 
indirectly influence the specific TCR recognition.   
The single-cell sequencing of TCRs specific for 
DQ2.5-glia-α1a and DQ2.5-glia-ω1 epitopes 
demonstrate the same V-gene bias. While V-
gene bias is not a new phenomenon among TCRs 
specific for immunodominant gluten epitopes 
(6,8-12), the high similarity in V-gene usage and 
biased expression of common V genes between 
DQ2.5-glia-α1a and DQ2.5-glia-ω1 epitopes is 
noteworthy. However, the TCR bias is not as 
striking as in TCRs specific to DQ2.5-glia-α2 
where we observe biased expression of TRBV7-2 
paired with TRAV26-1 and a conserved Arg in 
CDR3β (8-10,12) or in TCRs specific for DQ8-
glia-α1 with biased expression of TRAV26-
2/TRBV9 and a conserved Arg in CDR3α (6,11). 
In our hands, the TCR bias towards DQ2.5-glia-
α1a and DQ2.5-glia-ω1 is neither characterized 
by preferential TRAV/TRBV pairing nor 
conservation of CDR3 motifs that are common 
for both epitopes. This variability in TRAV/TRBV 
pairing and CDR3 region could possibly result in 
variable TCR docking patterns.  
Examining the wealth of TCR gene sequence 
data now accumulated for the four 
immunodominant HLA-DQ2.5-restricted gluten 
epitopes (DQ2.5-glia-α1a and DQ2.5-glia-ω1, 
DQ2.5-glia-α2 and DQ2.5-glia-ω2) in CeD (12), 
we observe that TRAV4 is among the most 
frequently expressed TRAVs in T cells specific 
for all of the four epitopes. This TRAV4 bias 
does not appear to be associated with a common 
TRBV usage or conservation of CDR3 sequences. 
The crystal structure of DQ2.5-glia-α1a-specific 
TCR using TRAV4 revealed that the TRAV4 bias 
against DQ2.5-glia-α1a is an effect of 
interactions between germline-encoded TCR 
residues, most prominently Tyr38α, with 
residues of the β-chain of HLA-DQ2.5 (Arg70β 
and Arg77β) (10). Similarly, HLA-
DQ2.5:DQ2.5-glia-α2 specific TCRs encoded by 
TRAV26-1, a phylogenetically close V gene with 
high sequence relatedness with TRAV4, formed 
analogous sets of interactions in ternary crystal 
structures. Therefore, we suggest that the 
common TRAV4 bias in TCRs specific for 
immunodominant gluten epitopes restricted by 
HLA-DQ2.5 could be an outcome of conserved 
interaction between germline residues encoded 
by TRAV4 and HLA-DQ2.5. 
CeD provides an opportunity to study the natural 
immune response in humans towards a natural 
antigenic system that comprises a vast array of 
similar peptide sequences. Here we show that 
despite minor differences in peptide:HLA-II 
topologies and high similarity in TCR V-gene 
usage, the majority of the T cells discriminate 
between the two homologous and 
immunodominant gluten epitopes. For CeD, this 
implicates that highly homologous peptides have 
the potential to engage separate T-cell 
populations thereby resulting in broader and 
more robust T-cell responses to gluten. Of 
general implication, the study underscores the 
exquisite sensitivity of TCRs to detect subtle 
differences in peptide:HLA-II complexes.  
Material and Methods 
 
Patient material 
We obtained ~60 ml of citrated full blood and six 
gut biopsies taken as part of a 
gastroduodenoscopy, using an Olympus H-180 
endoscope and a regular biopsy forceps 
(Olympus), from both untreated and treated CeD 
patients. PBMCs were isolated by Ficoll-based 
density gradient centrifugation from the blood 
samples and cryopreserved for later use. Gut 
biopsies were processed to obtain single-cell 
suspension prior to cryopreservation. In brief, 
freshly collected biopsies were washed twice 
with 2 mM EDTA in 2% FCS at 37 ºC for 10 
min (to remove epithelial layer) followed by 
collagenase digestion (1 mg/ml) at 37 ºC for 30-
60 min, homogenization by syringe and filtration. 
We used previously established and 
cryopreserved T-cell lines (TCLs) that had been 
generated from single gut biopsy, of which some 
are published (18,19). Two new TCLs (CD1174 
and CD1178) were generated by incubating gut 
biopsy with native chymotrypsin-digested gluten 
and deamidated chymotrypsin-digested gluten 
(both at 20 µg/mL) for 3-5 days followed by 
addition of interleukin (IL)-2/IL-15.  
 
Tetramer staining, cell enrichment and FACS  
Tetramers of recombinant HLA-DQ2.5 
covalently linked with gluten-derived peptides 
containing the T-cell epitope DQ2.5-glia-α1a 
peptide (QLQPFPQPELPY, underlined 9-mer 
core amino acid sequence) and DQ2.5-glia-α2 
peptide (PQPELPYPQPE) were produced and 
conjugated with phycoerythrin-labeled 
streptavidin (Invitrogen) or allophycocyanin-
labeled streptavidin (ProZyme) as described (20). 
Likewise, the HLA-DQ2.5:DQ2.5-glia-ω1 
(PQQPFPQPEQPFP) and HLA-DQ2.5:DQ2.5-
glia-ω2 (FPQPEQPFPWQP) tetramers were 
generated with the same protocol. Tetramer 
staining was performed on cryopreserved 
PBMCs, on single-cell suspension prepared from 
gut biopsies and on TCLs. In brief, the 
cryopreserved PBMCs were thawed and stained 
with the fluorochrome-conjugated tetramers (10 
µg/ml each), for 30-45 min at room temperature 
followed by bead enrichment of tetramer-binding 
cells before adding surface antibody mix. 
Cryopreserved single-cell suspensions of gut 
biopsies were thawed and stained with 
fluorochrome-conjugated tetramers (10 µg/ml) 
for 30-45 min at room temperature before adding 
surface antibody mix. Cryopreserved TCLs were 
thawed and stained directly with fluorochrome-
conjugated tetramers (10 µg/ml) for 2 hours at 37 
ºC before adding surface antibody mix. For 
PBMCs, cells within the singlet lymphocyte 
population were further gated to isolate tetramer-
binding CD4+ effector-memory T cells that were: 
CD3+, CD11c-, CD14-, CD15-, CD19-, CD56-, 
CD45RA-, CD62L-, and CD4+. For single-cell 
suspensions of gut biopsies, live cells within the 
singlet lymphocyte population were further gated 
to obtain tetramer-binding CD4+ T cells that 
were: CD3+, CD11c-, CD14-, CD15-, CD19-, 
CD56-, CD8- and CD4+. For T-cell lines, live 
cells within the singlet lymphocyte population 
were further gated to obtain tetramer-binding 
CD4+ T cells that were: CD3+, CD8- and CD4+. 
Finally, the populations of tetramer-binding 
CD4+ T cells were index sorted for single-cell 
TCR sequencing or for generation of TCCs by in 
vitro expansion. The sorting was performed with 
a FACS Aria II instrument (BD Biosciences) at 
the Flow Cytometry Core Facility (Oslo 
University Hospital) and the flow cytometry data 
was analyzed with FlowJo software (FlowJo 
LLC). The antibodies used in the study were: 
CD62L-PerCP/Cy5.5, CD14-Pacific Blue, 
CD15-Pacific Blue, CD19-Pacific Blue and 
CD56-Pacific Blue; CD3-FITC, CD11c-Horizon 
V450, CD4-APC or CD4-APC-H7 (from BD 
Biosciences); CD45RA-PE-Cy7 and CD3-
eVolve605, CD8-PE-Cy7 or CD8-PerCP 
(eBioscience). LIVE/DEAD marker fixable 
violet stain (Thermo Fischer Invitrogen) was 
used to exclude the dead cells. 
 
Generation and TCR sequencing of TCCs 
The TCCs were generated from tetramer-sorted 
CD4+ T cells and sequenced as described in 
previous publication (12). In brief, TCCs were 
generated using cloning by limited dilution and 
expanded without antigens followed by mRNA 
isolation, switching mechanism at the 5’-
terminus of the RNA transcript based cDNA 
synthesis, PCR amplification and finally Sanger 
sequencing. TCCs from patient CD442 and 
CD1340 used for Ala scans in the current study 
were generated in the course of another project 
(7). 
 
T-cell proliferation assay  
T-cell proliferation assays were carried out as 
described previously (21). In brief, 75,000 APCs 
(HLA-DQ2.5 homozygous Epstein-Barr virus 
(EBV)-transformed cells) were irradiated 75 Gy 
and incubated with 10 µM peptides at 37 oC for 
24 h before the adding 50,000 T cells. 48 hours 
later, cultures were pulsed with 1 µCi 3H-
thymidine followed by harvesting and 
scintillation counting after 16-20 hours. The 
TCCs were identified as peptide-specific if the 
stimulation index (ratio of cpm after antigen 
stimulation and cpm after medium stimulation) 
was higher than 3. 
 
Single-cell TCR gene sequencing 
We used a previously published protocol, based 
on nested PCR amplification using multiplex 
TRAV and TRBV primers, for single-cell TCR 
sequencing (22). The protocol was slightly 
modified by performing cDNA synthesis and the 
first PCR reaction in two separate steps. In short, 
single cells were sorted directly in 96-well plates 
containing 5 µl capture buffer (20 mM Tris-HCl 
(pH 8.0), 1% NP-40 and 1 U/µl RNase Inhibitor 
(optional). The cDNA mix (5 µl of 1X SSII RT 
buffer, 1 mM dNTP, 2.5 mM DDT, 1 µM oligo 
d(T), 1 µM reverse TRAC (5’-
AGTCAGATTTGTTGCTCCAGGCC-3’) and 
TRBC (5’-TTCACCCACCAGCTCAGCTCC-3’) 
primers, 1.5 U/µl RNase Inhibitor, 2.5 U/µl 
Superscript II in final 10 µl reaction volume) was 
added and cDNA synthesis was carried out at 42 
ºC for 50 min followed by an inactivation step at 
72 ºC for 10 min. The original protocol was 
followed to obtain a purified PCR product, 
which was then sequenced with 250-bp paired-
end sequencing using Illumina MiSeq platform 
at the Norwegian Sequencing Centre (Oslo 
University Hospital). All the raw data generated 
in this study has beenuploaded to the European 
Genome-phenome Archive 
(EGAS00001003245).                      
 
Processing of TCR gene sequences 
Processing of the raw sequencing data obtained 
from Illumina NGS was carried out in a 
multistep pipeline. The pipeline composed of: 
quality filtering of low-quality reads (Q < 30), 
annotation of the header with barcodes (row, 
plate and column) and gene (TRA/TRB) 
information, pairing and assembly of the 
annotated forward and reverse reads. These 
assembled reads were then collapsed to give up 
to three highest ranking reads (based on 
dupcount) to remove duplicates. In the next step 
V, D, J genes and CDR3 junction sequences 
were identified using IMGT-HighV-Quest online 
tool (23). A processing workflow implemented 
as an in-house Java program together with a 
custom MySQL database was used to further 
extract the sequences. In brief, only productive 
sequences with dupcount > 100 were collapsed 
based on identical V gene, J gene and CDR3 
(nucleotide level). These sequences were then re-
filtered, so that only T cells with at least one 
TCRα and TCRβ chain and dual TCRα or TCRβ 
chains (but not both dual TCRα and TCRβ, 
maximum 3 chains) were considered for 
downstream analysis. We then categorized T 
cells as a clonotype if they have identical V and J 
gene (subgroup level), together with identical 
CDR3 region allowing for one nucleotide 
mismatch. This data was then used for further 
analysis of clonal expansion and V-gene usage. 
The paired TCRα and TCRβ sequencing of 
single T cells isolated from TCLs of CeD 
patients CD364, CD373, CD412 and CD436 
used in V-gene usage analysis were generated in 
the course of another project for tracking 
clonotypes (7). 
 
CDR3 amino acid sequence alignment 
CDR3 amino acid sequence alignment was 
performed using CLC sequence viewer v8.0 
(CLC bio, Aarhus, Denmark) set to accurate with 
gap open penalty set to 20 and gap extension set 
to 4. 
 
HLA-DQ2.5 production, crystallization and 
structure determination 
HLA-DQ2.5:DQ2.5-glia-α1a-NC containing the 
epitope (QPFPQPELPYP) and HLA-
DQ2.5:DQ2.5-glia-ω1 containing the epitope 
(QPFPQPEQPFP) were expressed and purified 
as described previously  (10). Briefly, Fos/Jun 
zipper fusion constructs of the HLA-DQ2.5 α 
and β chains with each peptide linked to the N-
terminus of the HLA-DQ2.5 β chain were co-
expressed in Hi5 insect cells and purified via 
immobilized metal affinity and Superdex S200 
gel filtration chromatography. Prior to 
crystallization, the Fos/Jun zippers were 
removed by enterokinase cleavage followed by 
Hitrap-Q ion exchange chromatography. HLA-
DQ2.5:DQ2.5-glia-α1a and HLA-DQ2.5:DQ2.5-
glia-ω1 were concentrated to 8 mg/mL and 
crystallized via hanging drop vapour diffusion at 
room temperature using mother liquor containing 
23% PEG3350 and 0.1 M NaH2PO4 (pH 6). 
Crystals were cryoprotected in mother liquor 
supplemented with 20% glycerol and were flash 
frozen in liquid N2. X ray diffraction data was 
collected at the MX1 and MX2 beamlines of the 
Australian synchrotron and processed using the 
programs XDS (24) and Scala (25) from the 
CCP4 package (26). The structures of HLA-
DQ2.5:DQ2.5-glia-α1a and HLA-DQ2.5:DQ2.5-
glia-ω1 were solved via molecular replacement 
using Phaser (27), and contained two, and one 
protomers in the asymmetric unit, respectively. 
Structure models were generated by iterative 
rounds of model building in Coot (28) and 
restrained refinement in Phenix.  
 
The coordinates and structure factors have been 
deposited in the Protein Data Bank under the 
following accession codes: HLA-DQ2.5:DQ2.5-
glia-α1a, 6MFG; HLA-DQ2.5:DQ2.5-glia-ω1, 
6MFF.  
 
Surface plasmon resonance  
The surface plasmon resonance (SPR) 
experiments were conducted using Biacore 3000 
(GE Healthcare) with Biacore CAPture sensor 
chip. This analysis was performed in order to 
obtain equilibrium affinity constants of TCRs 
toward HLA-DQ2.5:DQ2.5-glia-α1a and HLA-
DQ2.5:DQ2.5-glia-ω1 constructs. TCRs were 
produced as described previously (10). The 
biotinylated ligands, HLA-DQ2.5:DQ2.5-glia-
α1a and HLA-DQ2.5:DQ2.5-glia-ω1 and HLA-
DQ2.5:DQ2.5-CLIP2 (ATPLLMQALPM, 
negative control for non-specific binding) were 
immobilized at 1000-1500 response units (RU) 
as previously shown (6,10). Flow cell surfaces 
were activated using 1:1 mixture of Biotin 
CAPture Reagent (Streptavidin and 
complementary oligonucleotide to the one on 
CAP surface) and HBS buffer (10 mM HEPES 
pH 7.4, 150 mM NaCl, 2 mM EDTA and 0.005% 
P20 detergent supplied by the manufacturer) at 
25 ℃ using flow rate of 5 𝜇L/min. Following 
injection of 1 mM biotin, decreasing 
concentrations of TCR in HBS buffer were 
passed over the flow cells for 1.5 min time 
interval. The maximum concentration of TCR 
for dilution series was 200 𝜇M. The affinities of 
each TCR for HLA-DQ2.5:DQ2.5-glia-α1a 
(LQPFPQPELPY), HLA-DQ2.5:DQ2.5-glia-
α1a-NC (QPFPQPELPYP) HLA-DQ2.5:DQ2.5-
glia-ω1 (QPFPQPEQPFP) constructs were tested 
by conducting four, two  and four independent 
experiments, respectively. The data for both 
HLA-DQ2.5-glia-α1a constructs were combined 
since there was no measurable difference. The 
equilibrium dissociation constant, KD, was 
determined by fitting the data into non-linear 
one-site specific binding model using GraphPad 
Prism version 7.0. 
 
Statistical analysis 
The Morisita-Horn index for analyzing similarity 
in TRAV and TRBV usage across TCRs specific 
for the four immunodominant epitopes was 
generated in R (3.3.2) with the use of the Vegan 
(2.4-2) package. We calculated pairwise 
similarities using sim.table function in Vegan 
package, setting 2 as the order of diversity 
measure (q) to generate the Morisita-Horn 
indices. 
 
Study approval 
The study was approved by Regional Committee 
for Medical and Health Research Ethics South-
East Norway (project 2010/2720). The patients 
participating in the study gave informed, written 
consent. 
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Figure legends 
FIGURE 1. DQ2.5-glia-α1a- and DQ2.5-glia-
ω1-specific CD4+ T cells in peripheral blood 
and gut of CeD patients. (A) Representative 
plot showing tetramer staining of CD4+ T cells 
with HLA:DQ gluten tetramers DQ2.5:DQ2.5-
glia-α1a and DQ2.5:DQ2.5-glia-ω1 in blood and 
gut of CeD patients. The peripheral blood 
mononuclear cells (PBMCs) were stained with 
tetramers followed by bead enrichment of the 
tetramer-positive cells. The flow plot shows 
tetramer-binding CD4+ effector-memory T-cells. 
*Frequency of tetramer-positive CD4+ T-cells 
per million total CD4+ T-cells. The gut biopsies 
were stained with HLA:DQ gluten tetramers, 
however bead enrichment was not performed. 
The plot in the figure shows tetramer-binding 
CD4+ T cells   (B) Relative ratio of CD4+ T cells 
positive to both DQ2.5:DQ2.5-glia-α1a- and 
DQ2.5:DQ2.5-glia-ω1-tetramers with CD4+ T 
cells that are positive to either of the two 
tetramers in samples obtained from 11 CeD 
patients. The horizontal line represents the mean 
value. (C) Staining of TCCs generated from 
HLA-DQ2.5:DQ2.5-glia-α1a or HLA-
DQ2.5:DQ2.5-glia-ω1 tetramer binding CD4+ T 
cells isolated from peripheral blood with HLA-
DQ2.5:gluten tetramers (DQ2.5-glia-α1a, 
DQ2.5-glia-α2, DQ2.5-glia-ω1, DQ2.5-glia-ω2) 
and CLIP2 tetramer. TCC1383P.A.2 is not 
included in the figure due to lack of TCC to 
carry out this staining (all tetramers attached 
with PE). However, TCC1383P.A.2 was tested 
in another staining experiment (tetramers 
attached with APC or PE) where it stained 
distinctly only with DQ2.5-glia-α1a (Data not 
shown). (D) T-cell proliferation of the TCCs 
generated from HLA-DQ2.5:DQ2.5-glia-α1a or 
HLA-DQ2.5:DQ2.5-glia-ω1 tetramer binding 
CD4+ T cells with panel peptides representing 
the known HLA-DQ2.5 restricted epitopes. 
DQ2.5-glia-α1a (QLQPFPQPELPY, underlined 
9-mer core amino acid sequence),  
DQ2.5-glia-α1b (PQPELPYPQPELPY),  
DQ2.5-glia-α2 (PQPELPYPQPQL),  
 DQ2.5-glia-γ1 (PEQPQQSFPEQERP),  
DQ2.5-glia-γ2 (GIIQPEQPAQL),  
DQ2.5-glia-γ3 (FPQQPEQPYPQQP),  
DQ2.5-glia-γ4a (FSQPEQEFPQPQ),  
DQ2.5-glia-γ4b (FPQPEQEFPQPQ),  
DQ2.5-glia-γ4c (TEQPEQPFPQP),  
DQ2.5-glia-γ5 (PEQPFPEQPEQ),   
DQ2.5-glia-ω1 (PQQPFPQPEQPFP),  
DQ2.5-glia-ω2 (FPQPEQPFPWQP), 
 DQ2.5-hor3 (PIPEQPQPYPQ) and  
DQ2.5-ave1a (YQPYPEQEEPFV). Two 
independent experiments were performed with 
measurements performed either in duplicate or 
triplicate. The data shows a representative plot 
where error bars represent mean±s.d for the 
triplicates.  
 
FIGURE 2. Effect of amino acid substitutions 
in the DQ2.5-glia-α1a and DQ2.5-glia-ω1 
epitopes on T-cell recognition. Reactivity 
patterns of (A) DQ2.5-glia-α1a-specific- and (B) 
DQ2.5-glia-ω1-specific TCCs to the single Ala-
substituted DQ2.5-glia-α1a and DQ2.5-glia-ω1 
peptides normalized to the wild-type response (1) 
are shown. The reactivity of (C) DQ2.5-glia-α1a-
specific- and (D) DQ2.5-glia-ω1-specific TCCs 
against chimeras: α1a_Qp7L, α1a_Fp9Y, 
ω1_Lp7Q and ω1_Yp9F peptides normalized to 
the wild-type response (1) are shown. The data 
shown is average of three independent 
experiments each with measurements performed 
in triplicates. Error bars represent mean±s.d for 
three experiments. 
 
FIGURE 3. DQ2.5-glia-α1a- and DQ2.5-glia-
ω1-specific TCRs. Unique T-cell clonotypes 
obtained from sequencing of TCRs (pairs of 
rearranged TCRα and TCRβ genes) of DQ2.5-
glia-α1a and DQ2.5-glia-ω1-specific T cells 
isolated directly from blood or gut biopsies of 
CeD patients using corresponding HLA:DQ 
tetramers were analyzed (A and B). Panel A 
shows frequencies of TRAV and TRBV usage and 
Morisita-Horn index for pair-wise comparison of 
similarity in TRAV and TRBV usage. Panel B 
shows frequency of the five most dominant 
TRAVs (upper panel) and TRBVs (lower panel) 
among the unique clonotypes observed in the 
respective TCR repertoire. The total number of 
clonotypes analyzed in each sample is denoted in 
X axis. CDR3α and CDR3β amino acid 
sequences of the DQ2.5-glia-α1a and DQ2.5-
glia-ω1-specific T cells isolated either directly 
from blood or gut biopsies or from in vitro 
cultured TCLs from gut biopsy were aligned and 
analyzed (C) for the usage of amino acids at 
different positions.  
 
FIGURE 4. Structures of HLA-
DQ2.5:HLA-DQ2.5-glia-α1a and HLA-
DQ2.5:HLA-DQ2-glia-ω1 complexes. 
HLA-DQ2.5 shown as cartoon and peptides as 
sticks, with HLA-DQ2.5 α-chain in light blue, β-
chain in yellow and DQ2.5-glia-α1a and DQ2.5-
glia-ω1 peptides in grey green, respectively. (A) 
Interactions between HLA-DQ2.5 and the 
DQ2.5-glia-α1a peptide (B) Interactions between 
HLA-DQ2.5 and the DQ2.5-glia-ω1 peptide. (C) 
Overlay of HLA-DQ2.5:DQ2.5-glia-α1a and 
HLA-DQ2.5:DQ2.5-glia-ω1 (top view) showing 
differences in the HLA-DQ2.5 β-chain helix. 
The pointers show the regions where the helix is 
shifted by >0.5Å (D) Overlay of HLA-
DQ2.5:DQ2.5-glia-α1a and HLA-DQ2.5:DQ2.5-
glia-ω1 (side view) showing differences in 
sidechain conformation in p9. (E) Electrostatic 
surface potential of HLA-DQ2.5:DQ2.5-glia-α1a, 
and (F) of HLA-DQ2.5:DQ2.5-glia-ω1. 
FIGURE 5. Surface plasmon resonance 
analysis of TCR interactions with HLA-
DQ2.5-glia-α1a and HLA-DQ2.5-glia-ω1. 
Sensorgram and binding curve fit of S2 (A, B)  
and L6 (C, D) affinity data into one-site specific 
binding model toward (A, C) HLA-DQ2.5-glia-
α1a and (B, D) HLA-DQ2.5-glia-ω1. For KD 
determination, all SPR data was derived from six 
(n=6) and four (n=4) independent experiments 
for HLA-DQ2.5-glia-α1a and HLA-DQ2.5-glia-
ω1, respectively. SPR, surface plasmon 
resonance. Req, Response at equilibrium. RU, 
response units. KD, dissociation constant. Error 
bars, s.d. 
